Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) hit a new 52-week high during

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and ra

Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT)

SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a c

Adaptive Biotechnologies (NASDAQ: ADPT - Get Free Report) and Charles River Laboratories Internation

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises

Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) shares hit a new 52-week high

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple my

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple my

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare

U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braz

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a c

Algert Global LLC decreased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 6

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies

Dimensional Fund Advisors LP lowered its stake in shares of Adaptive Biotechnologies Corporation (NA

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Ov

Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the sp

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the f

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and rais

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and ra

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the b

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Co

Adaptive Biotechnologies NASDAQ: ADPT reported second-quarter results marked by accelerating growth

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.10) per share which beat the

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.25) per share which missed t

SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechno

Caxton Associates LLP trimmed its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: A

D.A. Davidson and CO. reduced its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and ra

U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares j

William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve fl

BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and mainta

Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announ

Adaptive Biotechnologies plans to separate its businesses as clonoSEQ profitability and revenue grow

(Editor’s note: The lede, headline, futures and economic data were updated.) U.S. stock futures w

US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings;

HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open

Stock futures lower, Wiley & Sons and Vince Holding expected to report earnings, Dave & Bust

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company focused

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexib

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that ai

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal

JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overw

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and rais

Guggenheim analyst Subbu Nambi reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and m